公开(公告)号：US10968249B2

公开(公告)日：2021-04-06

申请号：US16878329

申请日：2020-05-19

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Jiang Long ,  Peng Dai ,  Xuechao Xing ,  Jing He

IPC: C07J41/00 ,  C07J43/00 ,  C07J9/00 ,  C07J51/00

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10689391B2

公开(公告)日：2020-06-23

申请号：US16217749

申请日：2018-12-12

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Jun Ma ,  Guoqiang Wang ,  Xuechao Xing ,  Ruichao Shen ,  Bin Wang

IPC: C07D491/048 ,  C07D493/04 ,  C07D487/04 ,  C07D417/14

Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10450306B2

公开(公告)日：2019-10-22

申请号：US15724919

申请日：2017-10-04

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jun Ma ,  Guoqiang Wang ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D261/08 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10450301B2

公开(公告)日：2019-10-22

申请号：US15988806

申请日：2018-05-24

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Bin Wang ,  Yat Sun Or

IPC: A61K31/4375 ,  A61K31/4725 ,  C07D401/14 ,  C07D471/04 ,  C07D471/08 ,  C07D417/14 ,  C07D451/02 ,  C07D451/06

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US10323061B2

公开(公告)日：2019-06-18

申请号：US15439531

申请日：2017-02-22

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yat Sun Or ,  Jing He ,  Guoqiang Wang ,  Xuechao Xing

IPC: C07J43/00 ,  A61K31/58

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

公开(公告)号：US10266560B2

公开(公告)日：2019-04-23

申请号：US14934122

申请日：2015-11-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Guoqiang Wang ,  Ruichao Shen ,  Xuechao Xing

IPC: A61K31/56 ,  A61K31/58 ,  C07J41/00 ,  C07J43/00

Abstract: The present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.

公开(公告)号：US20180362501A1

公开(公告)日：2018-12-20

申请号：US15988763

申请日：2018-05-24

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Brett Granger ,  Ruichao Shen ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D491/107 ,  C07D498/08 ,  C07D401/04

CPC classification number: C07D401/14 ,  C07D401/04 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US10138228B2

公开(公告)日：2018-11-27

申请号：US15597423

申请日：2017-05-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Yong He ,  Ruichao Shen ,  Xuechao Xing ,  Brett Granger ,  Bin Wang ,  Jun Ma ,  Jing He ,  Jiang Long ,  Guoqiang Wang

IPC: A61K31/42 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US20180327388A1

公开(公告)日：2018-11-15

申请号：US15979128

申请日：2018-05-14

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jiang Long ,  Jun Ma ,  Xuechao Xing ,  Yong He ,  Brett Granger ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D417/14 ,  C07D405/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US10080741B2

公开(公告)日：2018-09-25

申请号：US15497268

申请日：2017-04-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Brett Granger ,  Ruichao Shen ,  Xuechao Xing ,  Bin Wang ,  Jun Ma ,  Jing He ,  Jiang Long ,  Yong He ,  Guoqiang Wang

IPC: C07D261/08 ,  C07D413/12 ,  A61K31/42 ,  C07D261/06 ,  C07D413/04

CPC classification number: A61K31/42 ,  C07D261/06 ,  C07D261/08 ,  C07D413/04 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.